--- title: "MK-677 Dosage Guide [2026] | BodyHackGuide" url: https://www.bodyhackguide.co/guides/dosage/mk-677 description: "Complete MK-677 (Ibutamoren) dosage guide with protocols, calculator, safety info, and where to buy. Updated for 2026." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Growth Hormone / IGF-1 Axis Phase II # MK-677 (Ibutamoren) Dosage Guide: Protocols, Calculator & Safety Everything you need to know about MK-677 (Ibutamoren) dosing: protocols, safety, and where to buy. Dose Range 10,000–25,000 mcg (10–25 mg) oral daily Frequency Once daily, typically at bedtime Cycle Length 8–16 weeks; some use long-term (6+ months) with monitoring Half-Life ~24 hours (oral) ## Administration Routes oral Dosage Calculator Calculate exact dosing for MK-677 (Ibutamoren). https://www.bodyhackguide.co/tools/dosage ## Dosing Protocols Beginner **Goal: establish tolerance at a conservative dose before committing to the full 25 mg/day protocol.** **Low-dose MK-677 — weeks 1-4** - **Dose:** 10 mg orally, once daily - **Timing:** Pre-bed, on an empty stomach (≥2 hours after last meal) - **Why pre-bed:** The 24-hour half-life means timing is less critical than for injectable GHS, but pre-bed dosing (a) maximizes sleep-architecture benefit, (b) reduces perceived appetite effect during waking hours, and (c) aligns with the nocturnal GH burst - **Why 10 mg vs 25 mg:** At 10 mg, IGF-1 typically rises ~40-50% with substantially less water retention, appetite stimulation, and glucose effect than the 25 mg dose. For many users 10 mg provides 70-80% of the benefit with 30% of the side-effect burden **Form factors** - **Capsules** — most common; 10 mg capsule or split 25 mg capsule - **Oral liquid** — faster absorption, easier dose adjustment; typical concentration 25 mg/mL - **Sublingual / dissolvable tablet** — marginal bioavailability advantage; negligible vs swallowed capsule **What to expect in weeks 1-4** - Week 1: vivid dreams, evening hunger, mild water retention (~1 kg scale weight) - Week 2-3: improved recovery and sleep quality; hunger stabilizes - Week 4: IGF-1 rising toward steady state; subjective benefits consolidating **Required monitoring for beginners** - **Baseline:** IGF-1, fasting glucose, HbA1c, CBC, CMP, lipid panel, PSA (men >40), thyroid - **Week 4:** IGF-1, fasting glucose - **Scale weight daily** — to track fluid retention trend **When NOT to proceed to intermediate** - Fasting glucose rise >10 mg/dL from baseline → hold dose escalation - Scale weight up >2 kg with persistent edema → hold or reduce - Any carpal tunnel symptoms → hold or reduce - No subjective benefit at week 4 on 10 mg → consider the underlying question of whether MK-677 is the right tool vs injectable GHS **At week 4, reassess.** If tolerance is good and effect is modest, progress to 20-25 mg/day. If 10 mg is producing the desired effects, many users stay there indefinitely — there is no mandatory escalation. Standard **Goal: the standard 25 mg/day MK-677 protocol, as used in the Nass 2008 trial and the reference biohacking protocol.** **Standard MK-677 — weeks 1-12 (or continuous within cycle)** - **Dose:** 25 mg orally, once daily - **Timing:** Pre-bed, empty stomach preferred (≥2 hours post-meal) - **Cycle length:** 8-16 weeks on / 4-6 weeks off is the conservative approach; the Nass trial ran 2 years continuous with good tolerance in most patients **Why 25 mg specifically** - Established dose from Murphy 1998 PK and Chapman 1996 dose-response — above 25 mg the IGF-1 dose-response plateaus while side effects continue to scale - Validated in the longest human trial (Nass 2008, 2 years) - Balance point between effect size and side-effect burden **Timing nuances** - **Pre-bed empty stomach:** standard; maximizes sleep benefit - **Morning fasted:** alternative for users whose evening hunger is too disruptive; does not reduce efficacy significantly because of the 24h half-life - **With food:** reduces absorption mildly (~15%); most users can take MK-677 with food if empty stomach is not practical **Stacking at this tier** MK-677 can be stacked with but does not typically combine with injectable GHS peptides (redundant at the receptor — see stacking notes). Common co-interventions: - **Testosterone (https://www.bodyhackguide.co/compound/enclomiphene) or TRT** — complementary hormone axes - **Semaglutide (https://www.bodyhackguide.co/compound/semaglutide) / Tirzepatide (https://www.bodyhackguide.co/compound/tirzepatide)** — MK-677 can counteract the GLP-1-induced appetite suppression if lean mass preservation is the goal (the appetite dimension runs in opposite directions — be deliberate about which you want to win) - **BPC-157 (https://www.bodyhackguide.co/compound/bpc-157) + TB-500 (https://www.bodyhackguide.co/compound/tb-500)** — connective tissue repair synergy with GH/IGF-1 elevation - **Metformin 500-1000 mg/day** — off-label; counters the MK-677-induced insulin resistance; commonly stacked in bodybuilding protocols **Bloodwork** - **Baseline:** IGF-1, fasting glucose, HbA1c, insulin, CBC, CMP, lipid panel, PSA (men >40), thyroid, estradiol - **Week 4:** IGF-1, fasting glucose, insulin - **Week 8:** Full panel - **End of cycle:** Full panel + reassess - **Scale weight and waist measurement weekly** **When to dose-reduce or stop** - IGF-1 >300 ng/mL (supraphysiologic) → reduce to 15 mg or cycle off - HbA1c rising >0.3 points → counter with metformin or cycle off - Persistent edema, carpal tunnel, or new cardiac symptoms → stop and reassess - Any chest pain, dyspnea, or CHF-like symptoms (rare but documented) → stop immediately and seek medical evaluation Advanced **Goal: optimize MK-677 effects within the physiologic envelope while managing its characteristic side-effect profile. For experienced users with full lab monitoring.** **Pulsed 25 mg protocol with insulin-sensitizer co-therapy - 12-24 weeks** For users pursuing extended MK-677 use with managed side effects: - **MK-677:** 25 mg orally pre-bed - **Metformin:** 500-1000 mg/day (off-label insulin-sensitizer) - **Optional addition:** Enclomiphene (https://www.bodyhackguide.co/compound/enclomiphene) 12.5-25 mg/day if TRT-like effects without exogenous testosterone are desired **Rationale:** Metformin directly addresses MK-677's primary durable side effect (glucose intolerance) while preserving the GH/IGF-1 benefits. This is not Merck-tested; it is extrapolation from known metformin pharmacology and routine bodybuilding practice. **High-dose protocol - NOT RECOMMENDED** Some bodybuilding protocols use 50 mg or higher MK-677. The data is clear: - Chapman 1996 showed dose-response plateaus above 25 mg for IGF-1 - Side effects continue to scale linearly: more water retention, more hunger, more glucose effect - No evidence of clinically meaningful incremental benefit - Do not exceed 25 mg/day **Split-dose protocol - alternative for hunger management** For users whose evening hunger is intolerable: - 12.5 mg AM (morning fasted) + 12.5 mg pre-bed - 24h half-life means this is pharmacokinetically similar to once-daily dosing - Splits the appetite signal across the day rather than concentrating it in the evening **Cycling strategies** - **Standard:** 12 weeks on / 4-6 weeks off - **Long cycle:** 24 weeks on / 8 weeks off (the Nass-trial-reference approach) - **Continuous:** validated in Nass 2008 for 2 years; not generally recommended for healthy biohackers pursuing longevity protocols due to long-term safety uncertainty **Body recomposition with GLP-1 therapy** MK-677 + semaglutide / tirzepatide is the recomposition stack for users who want: - GLP-1-driven fat loss - GH/IGF-1 lean mass preservation - Appetite management - GLP-1 suppresses appetite more than MK-677 stimulates it at clinical doses, so the net is still hypocaloric but less aggressively than GLP-1 alone **Contraindications specific to advanced dosing** - Any history of CHF or NYHA II-IV - absolute (Adunsky 2011 hip-fracture CHF signal) - Uncontrolled T2DM - use with extreme caution and endocrinology supervision - Active malignancy - absolute - Diabetic retinopathy - relative contraindication - History of acromegaly or pituitary adenoma - absolute ## Weight-Based Dosing Not weight-based. Standard doses of 10–25 mg. ## Commonly Stacked With **Tier 1 — Complementary hormone axes (recommended):** - **Testosterone (https://www.bodyhackguide.co/compound/enclomiphene) / TRT / enclomiphene** — HPG and GH axes are independent; combined optimization is standard practice - **Semaglutide (https://www.bodyhackguide.co/compound/semaglutide) / Tirzepatide (https://www.bodyhackguide.co/compound/tirzepatide)** — recomposition stack; MK-677 preserves lean mass during GLP-1-driven caloric deficit; be deliberate about appetite direction (GLP-1 suppresses, MK-677 stimulates) - **Metformin 500-1000 mg/day** — off-label insulin-sensitizer counters MK-677-induced glucose intolerance; common bodybuilding adjunct - **BPC-157 (https://www.bodyhackguide.co/compound/bpc-157) + TB-500 (https://www.bodyhackguide.co/compound/tb-500)** — connective tissue repair synergy; GH/IGF-1 elevation amplifies local healing mechanisms **Tier 2 — Metabolic / longevity stacks:** - **NAD+ (https://www.bodyhackguide.co/compound/nad) / NMN** — mitochondrial support for increased protein synthesis and fat oxidation - **Epithalon (https://www.bodyhackguide.co/compound/epithalon)** — longevity-framed; pairs with MK-677's sustained GH/IGF-1 elevation - **GHK-Cu (https://www.bodyhackguide.co/compound/ghk-cu)** — skin and connective tissue regeneration synergy **Tier 3 — Selective additions:** - **L-carnitine / ALCAR** — mild support for the fat oxidation MK-677 enables via GH/IGF-1 - **Creatine 5 g/day** — standard anabolic; additive to MK-677's lean mass effect - **MOTS-c (https://www.bodyhackguide.co/compound/mots-c)** — mitochondrial peptide; theoretical synergy with GH-mediated metabolic effects **DO NOT stack:** - **Ipamorelin (https://www.bodyhackguide.co/compound/ipamorelin)** — redundant at the GHS-R1a receptor; no additive benefit; side-effect burden stacks. If you want 24h IGF-1 elevation, use MK-677 alone. If you want discrete pulses, use ipamorelin alone - **GHRP-2, GHRP-6, hexarelin** — same redundancy issue - **Tesamorelin (https://www.bodyhackguide.co/compound/tesamorelin)** — different receptor (GHRHR vs GHS-R1a) and _could_ be combined, but the sustained 24h MK-677 signal already amplifies the nocturnal GHRH pulse without needing exogenous GHRH; the combination adds side-effect burden without proportional benefit in most protocols. Advanced users occasionally stack these but it's unusual - **CJC-1295 with DAC (https://www.bodyhackguide.co/compound/cjc-1295-dac)** — the continuous GH elevation of both drugs stacks and produces the worst-case profile of sustained supra-physiologic GH/IGF-1; not recommended - **Exogenous recombinant GH (Somatropin)** — defeats the purpose; use one or the other - **High-dose corticosteroids (chronic systemic)** — suppress the GH axis and blunt MK-677 efficacy **Practical notes** - MK-677 is oral; stacking considerations are primarily about additive side effects (fluid retention, hunger, glucose), not injection-site or pharmacokinetic compatibility - For users on TRT who want the maximum anabolic profile without the injections: MK-677 + testosterone + metformin is the common configuration - For users on GLP-1 therapy, MK-677 at 10 mg (not 25 mg) is the more moderate configuration — reduces the appetite conflict between the two drugs ## Side Effects & Safety MK-677 has the **most pronounced side-effect profile of any GHS compound** - specifically because its 24-hour half-life produces sustained rather than pulsatile receptor engagement. Users should expect all of the side effects listed below at some frequency. **Common (>20% of users, nearly universal at 25 mg/day)** - **Appetite increase** - the signature MK-677 effect; direct ghrelin-receptor agonism on hypothalamic feeding neurons. Can increase caloric intake by 20-30% if not actively controlled. Primarily evening and nocturnal (because that's when the pre-bed dose peaks) - **Water retention / mild peripheral edema** - fluid-shift from GH and IGF-1 elevation plus sustained ghrelin-receptor tone. Typically 1-3 kg of scale weight in the first 2 weeks; settles by week 4 in most users; peripheral edema should resolve by week 6-8 - **Lethargy / "heavy" feeling** - particularly in the first 2-3 weeks; fluid-related; most users report this resolves but some stay lethargic through the cycle - **Vivid dreams / altered sleep** - usually positive (deeper SWS) but can be disruptive in the first week - **Transient mild numbness / tingling in hands** - water-retention-related peripheral nerve compression; early sign to reduce dose **Uncommon (5-20%)** - **Insulin resistance / elevated fasting glucose** - real and dose-dependent; HbA1c rises ~0.1-0.3% in Phase II data; meaningful for pre-diabetics and diabetics - **Mild carpal tunnel symptoms** - fluid-related; resolves on cessation; should prompt dose reduction - **Joint stiffness** - IGF-1-mediated connective tissue effect; typically weeks 4-8; often resolves with continued dosing - **Mild elevation in liver enzymes (ALT/AST)** - usually within normal limits; monitor but rarely clinically significant **Rare but important** - **Congestive heart failure signal** - the CHF safety signal for MK-677 comes from the Adunsky 2011 hip-fracture Phase IIb trial (25 mg/day, N=123), which was terminated early after a small number of frail elderly patients developed CHF; it is attributed to fluid retention in vulnerable populations. The 2-year Nass trial in healthy older adults reported no CHF. This is the primary safety signal driving the "not in CHF, not in severe cardiac disease" contraindication - **Pituitary desensitization concerns** - theoretical; not conclusively demonstrated in the 2-year trial but some users report reduced subjective response after 3-4 months of continuous dosing - **Elevated prolactin** - rare at clinical doses but reported at higher doses; unique among "selective" GHS agents but dose-related **Insulin resistance - the honest framing** MK-677's effect on glucose metabolism is the most clinically important difference vs injectable GHS peptides. Mechanism: - Direct GH-mediated hepatic glucose output increase - Sustained ghrelin-receptor activation has independent glucose-intolerant effects - Water retention complicates interpretation of labs In Phase II data, HbA1c rose ~0.1-0.3% on MK-677 25 mg/day over 6-24 months. This is **clinically small but not trivial**: - For healthy users: usually not clinically meaningful - For pre-diabetics (fasting glucose 100-125 or HbA1c 5.7-6.4%): can push into overt T2DM territory - For established T2DM: requires insulin/metformin adjustment and close monitoring **What MK-677 does NOT do (or does less than)** - Does NOT significantly elevate cortisol (unlike GHRP-6 / hexarelin) - Does NOT significantly elevate ACTH - Does NOT cause injection-site reactions (it's oral) - Does NOT cause the pulse-amplitude sleep disturbance some users get from injectable GHS **Long-term uncertainty** The Nass 2-year trial is the longest data we have. Beyond 2 years, safety is extrapolated: - Chronic hyperinsulinism effects - IGF-1-related cancer risk - Pituitary somatotroph reserve - Cardiovascular outcomes in the broader population (the Nass cohort was older adults, not the 25-45 year old biohacker demographic) **Users should monitor:** fasting glucose, HbA1c, IGF-1 (baseline and 4-6 weeks into dosing), PSA (men >40), and regular blood pressure. Cycling (8-16 weeks on / 4-8 weeks off) is the conservative approach although the mechanistic need for cycling is debated - unlike CJC-1295-DAC, MK-677 does not produce full somatotroph desensitization at clinical doses. Contraindications **Absolute contraindications** - **History of congestive heart failure (CHF)** or any NYHA class II-IV cardiac dysfunction - the Adunsky 2011 hip-fracture Phase IIb trial (25 mg/day, N=123) was terminated early after a CHF safety signal in frail elderly patients; MK-677's water retention and sustained GH elevation can precipitate decompensation in vulnerable hearts - **Active malignancy** - GH/IGF-1 axis may accelerate tumor growth. No direct MK-677 cancer data but inferred from general GH/IGF-1 literature ([Renehan et al., 2004]) - **Active diabetic retinopathy** (proliferative or severe non-proliferative) - GH elevation can worsen retinopathy - **History of acromegaly or pituitary adenoma** - superimposing sustained exogenous GH amplification on an already-hyperactive axis risks accelerating tumor growth and acromegalic progression - **Pregnancy or breastfeeding** - no safety data; do not use - **Age <18** - pediatric GHD is managed with sermorelin or recombinant GH under endocrinology supervision, not MK-677 **Relative contraindications (consult physician before use)** - **Type 2 diabetes or pre-diabetes** - MK-677 produces measurable glucose intolerance; use requires close monitoring and usually metformin co-therapy - **Uncontrolled hypertension** - fluid retention can exacerbate blood pressure - **History of carpal tunnel syndrome** - fluid retention and connective tissue expansion can worsen symptoms - **Hypothyroidism** - optimize thyroid first - **Chronic kidney disease (CKD stage III+)** - fluid retention can contribute to edema; dose reduction and close monitoring - **History of pituitary or hypothalamic surgery or radiation** - altered somatotroph response; unpredictable **Drug interactions** - **Insulin and oral hypoglycemics** - MK-677 impairs glucose tolerance; antidiabetic medication may need adjustment - **Corticosteroids** (chronic systemic) - suppress GH axis and blunt MK-677 response - **CYP3A4 inhibitors/inducers** - MK-677 is CYP3A4 metabolized; major inhibitors (ketoconazole, ritonavir) can elevate plasma levels; inducers (rifampin, carbamazepine) can reduce efficacy - **Exogenous GH (Somatropin)** - do not combine - **Other GHS peptides or CJC-1295-DAC** - do not combine (redundant, additive side effects) **Specific drug combinations that require caution** - **SSRI + MK-677** - no direct interaction but both can cause fluid retention; monitor - **NSAID chronic + MK-677** - both retain fluid; monitor edema - **Statins + MK-677** - no specific interaction; standard monitoring **Monitoring requirements** - **Baseline:** IGF-1, fasting glucose, HbA1c, insulin, complete metabolic panel, thyroid panel, CBC, lipid panel, PSA (men >40), echocardiogram if any cardiac history - **Week 4-6:** IGF-1, fasting glucose, insulin - **Week 8-12:** Full panel + blood pressure + weight trend - **Every 12 weeks on long-term therapy:** Full panel - **Annually:** Full panel + consider imaging if symptomatic **Discontinuation criteria** Stop MK-677 and consult a clinician if you develop: - Any chest pain, dyspnea, peripheral edema with weight gain >3 kg, orthopnea - possible CHF; urgent - New or worsening carpal tunnel symptoms - IGF-1 > 350 ng/mL (supraphysiologic in most adults) - Fasting glucose consistently >115 mg/dL or HbA1c rising >0.4 points despite metformin - Any new palpable mass, changing mole, unexplained weight loss (cancer workup) - Severe headache, visual changes (rule out pituitary pathology) - Unexplained fatigue, edema, or rapid weight gain (assess fluid balance, thyroid, glucose) Check interactions with the Interaction Checker → (https://www.bodyhackguide.co/tools/interaction-checker) ## Additional Notes **Standard therapeutic dose: 25 mg orally, once daily, pre-bed.** This is the dose used in every major MK-677 trial (Nass 2008, Chapman 1996, Murphy 1998, Copinschi 1997, Adunsky 2011). Doses above 25 mg do not produce proportional IGF-1 elevation — the dose-response plateaus — while side-effect burden (water retention, hunger, glucose intolerance) continues to scale. **Low-dose option: 10 mg orally, once daily** For users wanting most of the IGF-1 and sleep benefits with substantially reduced side effects: - 10 mg produces ~40-50% IGF-1 elevation vs ~80-100% at 25 mg - Water retention is typically <1 kg vs 2-3 kg at 25 mg - Appetite stimulation is substantially milder - Glucose effect is minimal For many biohackers, 10 mg/day is the sweet spot — particularly for longevity-oriented rather than body-composition-oriented protocols. **Dosing route and form** - **Oral capsules:** most common, most convenient - **Oral liquid:** 25 mg/mL is standard; measure with oral syringe; faster absorption - **Sublingual:** marginal bioavailability advantage; negligible for practical purposes **Fasted state improves absorption** — approximately 15% higher Cmax in fasted vs fed state. Pre-bed (2+ hours post-meal) is the standard timing for (a) absorption, (b) sleep architecture benefit, (c) alignment with nocturnal GH burst. **NOT dose-dependent on body weight** — the MK-677 dose is fixed at 10 or 25 mg regardless of body mass. No weight-adjusted dosing. **Dose conversions (25 mg/mL oral liquid)** - 10 mg = 0.4 mL - 15 mg = 0.6 mL - 25 mg = 1.0 mL - Use an oral (not insulin) syringe; peptide injection syringes are graduated for injection volumes, not oral dosing **Timing alternatives** - **Pre-bed** (standard): maximizes sleep benefit; peak ghrelin signal overlaps with lights-out - **Morning fasted:** for users whose evening hunger is too disruptive; minimal efficacy penalty due to 24h half-life - **Split 12.5 mg AM + 12.5 mg PM:** advanced option to spread appetite stimulation across the day **Interactions with nutrition** - Food reduces absorption ~15%; empty stomach preferred but not essential - Alcohol does not meaningfully interact; avoid within 4 hours of dosing for sleep quality - Caffeine is neutral - High-fat meal before dosing slightly reduces Cmax but increases time-to-peak **Dose adjustments in specific populations** - **Renal impairment (eGFR <60):** dose reduction typically not required; monitor - **Hepatic impairment:** use with caution; MK-677 is hepatically metabolized - **Age >65:** standard dose used in the Nass trial; no specific adjustment - **Active T2DM:** 10 mg starting dose with close glucose monitoring; escalate only if glucose control maintained with metformin or equivalent See the MK-677 Dosage Guide (https://www.bodyhackguide.co/guides/dosage/mk-677) for detailed protocol specifics. Where to Buy MK-677 (Ibutamoren) Compare 2 listings across 2 vendors, from $74.99 https://www.bodyhackguide.co/compound/mk-677 ## Frequently Asked Questions What is the recommended MK-677 (Ibutamoren) dosage? The typical dose range for MK-677 (Ibutamoren) is 10,000–25,000 mcg (10–25 mg) oral daily. It is usually administered Once daily, typically at bedtime. Always start with the lowest effective dose. How often should I take MK-677 (Ibutamoren)? Once daily, typically at bedtime Does MK-677 (Ibutamoren) need to be cycled? Yes, typical cycle length is 8–16 weeks; some use long-term (6+ months) with monitoring. What are MK-677 (Ibutamoren) side effects? Where can I buy MK-677 (Ibutamoren)? Compare 2 listings from 2 vendors on our price comparison page, starting from $74.99. MK-677 (Ibutamoren) Full Profile Research data, mechanisms, and pricing https://www.bodyhackguide.co/compound/mk-677 Interaction Checker Check drug & compound interactions https://www.bodyhackguide.co/tools/interaction-checker ## Related Dosage Guides All Guides (https://www.bodyhackguide.co/guides) ### CJC-1295 (Mod GRF 1-29) Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/cjc-1295 ### CJC-1295 with DAC Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/cjc-1295-with-dac ### CJC-1295 with DAC Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/cjc-1295-dac ### GHRP-2 Growth Hormone / IGF-1 Axis · Dosage Guide https://www.bodyhackguide.co/guides/dosage/ghrp-2 Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Article", "headline": "MK-677 Dosage Guide [2026]", "description": "Complete MK-677 (Ibutamoren) dosage guide with protocols, calculator, safety info, and where to buy. Updated for 2026.", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/bhglogo.png" } } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is the recommended MK-677 (Ibutamoren) dosage?", "acceptedAnswer": { "@type": "Answer", "text": "The typical dose range for MK-677 (Ibutamoren) is 10,000–25,000 mcg (10–25 mg) oral daily. It is usually administered Once daily, typically at bedtime. Always start with the lowest effective dose." } }, { "@type": "Question", "name": "How often should I take MK-677 (Ibutamoren)?", "acceptedAnswer": { "@type": "Answer", "text": "Once daily, typically at bedtime" } }, { "@type": "Question", "name": "Does MK-677 (Ibutamoren) need to be cycled?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, typical cycle length is 8–16 weeks; some use long-term (6+ months) with monitoring." } }, { "@type": "Question", "name": "What are MK-677 (Ibutamoren) side effects?", "acceptedAnswer": { "@type": "Answer", "text": "MK-677 has the **most pronounced side-effect profile of any GHS compound** - specifically because its 24-hour half-life produces sustained rather than pulsatile receptor engagement. Users should expect all of the side effects listed below at some frequency.\n\n**Common (>20% of users, nearly universal at 25 mg/day)**\n\n- **Appetite increase** - the signature MK-677 effect; direct ghrelin-receptor agonism on hypothalamic feeding neurons. Can increase caloric intake by 20-30% if not actively controlled. Primarily evening and nocturnal (because that's when the pre-bed dose peaks)\n- **Water retention / mild peripheral edema** - fluid-shift from GH and IGF-1 elevation plus sustained ghrelin-receptor tone. Typically 1-3 kg of scale weight in the first 2 weeks; settles by week 4 in most users; peripheral edema should resolve by week 6-8\n- **Lethargy / \"heavy\" feeling** - particularly in the first 2-3 weeks; fluid-related; most users report this resolves but some stay lethargic through the cycle\n- **Vivid dreams / altered sleep** - usually positive (deeper SWS) but can be disruptive in the first week\n- **Transient mild numbness / tingling in hands** - water-retention-related peripheral nerve compression; early sign to reduce dose\n\n**Uncommon (5-20%)**\n\n- **Insulin resistance / elevated fasting glucose** - real and dose-dependent; HbA1c rises ~0.1-0.3% in Phase II data; meaningful for pre-diabetics and diabetics\n- **Mild carpal tunnel symptoms** - fluid-related; resolves on cessation; should prompt dose reduction\n- **Joint stiffness** - IGF-1-mediated connective tissue effect; typically weeks 4-8; often resolves with continued dosing\n- **Mild elevation in liver enzymes (ALT/AST)** - usually within normal limits; monitor but rarely clinically significant\n\n**Rare but important**\n\n- **Congestive heart failure signal** - the CHF safety signal for MK-677 comes from the Adunsky 2011 hip-fracture Phase IIb trial (25 mg/day, N=123), which was terminated early after a small number of frail elderly patients developed CHF; it is attributed to fluid retention in vulnerable populations. The 2-year Nass trial in healthy older adults reported no CHF. This is the primary safety signal driving the \"not in CHF, not in severe cardiac disease\" contraindication\n- **Pituitary desensitization concerns** - theoretical; not conclusively demonstrated in the 2-year trial but some users report reduced subjective response after 3-4 months of continuous dosing\n- **Elevated prolactin** - rare at clinical doses but reported at higher doses; unique among \"selective\" GHS agents but dose-related\n\n**Insulin resistance - the honest framing**\n\nMK-677's effect on glucose metabolism is the most clinically important difference vs injectable GHS peptides. Mechanism:\n- Direct GH-mediated hepatic glucose output increase\n- Sustained ghrelin-receptor activation has independent glucose-intolerant effects\n- Water retention complicates interpretation of labs\n\nIn Phase II data, HbA1c rose ~0.1-0.3% on MK-677 25 mg/day over 6-24 months. This is **clinically small but not trivial**:\n- For healthy users: usually not clinically meaningful\n- For pre-diabetics (fasting glucose 100-125 or HbA1c 5.7-6.4%): can push into overt T2DM territory\n- For established T2DM: requires insulin/metformin adjustment and close monitoring\n\n**What MK-677 does NOT do (or does less than)**\n\n- Does NOT significantly elevate cortisol (unlike GHRP-6 / hexarelin)\n- Does NOT significantly elevate ACTH\n- Does NOT cause injection-site reactions (it's oral)\n- Does NOT cause the pulse-amplitude sleep disturbance some users get from injectable GHS\n\n**Long-term uncertainty**\n\nThe Nass 2-year trial is the longest data we have. Beyond 2 years, safety is extrapolated:\n- Chronic hyperinsulinism effects\n- IGF-1-related cancer risk\n- Pituitary somatotroph reserve\n- Cardiovascular outcomes in the broader population (the Nass cohort was older adults, not the 25-45 year old biohacker demographic)\n\n**Users should monitor:** fasting glucose, HbA1c, IGF-1 (baseline and 4-6 weeks into dosing), PSA (men >40), and regular blood pressure. Cycling (8-16 weeks on / 4-8 weeks off) is the conservative approach although the mechanistic need for cycling is debated - unlike CJC-1295-DAC, MK-677 does not produce full somatotroph desensitization at clinical doses." } }, { "@type": "Question", "name": "Where can I buy MK-677 (Ibutamoren)?", "acceptedAnswer": { "@type": "Answer", "text": "Compare 2 listings from 2 vendors on our price comparison page, starting from $74.99." } } ] }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Guides", "item": "https://www.bodyhackguide.co/guides" }, { "@type": "ListItem", "position": 3, "name": "Dosage Guides", "item": "https://www.bodyhackguide.co/guides" }, { "@type": "ListItem", "position": 4, "name": "MK-677 (Ibutamoren) Dosage", "item": "https://www.bodyhackguide.co/guides/dosage/mk-677" } ] } ] ```